Want to see ANGO full AI Analyst Report?
ANGO Stock Chart & Stats
$15.69
$0.07(0.52%)
At close: 4:00 PM EDT
$15.69
$0.07(0.52%)
Day’s Range― - ―
52-Week Range$9.39 - $16.29
Previous Close$13.66
Volume403.10K
Average Volume (3M)396.14K
Market Cap
$645.61M
Enterprise Value$435.76
Total Cash (Recent Filing)$53.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Oct 01, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding41,332,390
10 Day Avg. Volume241,082
30 Day Avg. Volume396,145
Financial Highlights & Ratios
PEG Ratio-2.06
Price to Book (P/B)2.65
Price to Sales (P/S)1.42
P/FCF Ratio891.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.00Price Target Upside33.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$337.40M
Bulls Say, Bears Say
Bulls Say
Med Tech GrowthAbove-market growth across Med Tech platforms is strengthening the company’s revenue mix toward faster-growing procedure markets. Continued expansion in these platforms can support durable demand, operating leverage, and increasing strategic relevance.
Clinical And Coverage ProgressClinical evidence, dedicated reimbursement coding, and Medicare coverage reduce adoption barriers for NanoKnife in prostate and liver cancer. These developments can support broader physician use, procedure growth, and recurring disposable utilization over multiple periods.
Financial FlexibilityA debt-free balance sheet and substantial cash reserve provide flexibility to fund clinical development, commercialization, and product expansion without significant financing pressure. Healthy gross margins also create a foundation for eventual operating leverage.
Bears Say
Persistent Net LossesOngoing GAAP and adjusted losses show that revenue growth and gross profit have not yet translated into sustainable bottom-line profitability. Continued losses may constrain reinvestment capacity and leave results dependent on successful execution and future scale.
Cost And Tariff PressureTariffs and higher R&D and SG&A spending are absorbing a meaningful share of gross profit. If these costs persist while commercialization investments remain elevated, margin expansion and the path to sustained positive earnings could be delayed.
Uneven Core Segment GrowthSlower Med Device growth and volatility in AngioVac create dependence on a smaller set of high-growth Med Tech products. Competitive thrombectomy markets and uneven capital sales may make consolidated growth and resource planning less predictable.
AngioDynamics News
ANGO FAQ
What was AngioDynamics’s price range in the past 12 months?
AngioDynamics lowest stock price was $9.39 and its highest was $16.29 in the past 12 months.
What is AngioDynamics’s market cap?
AngioDynamics’s market cap is $645.61M.
When is AngioDynamics’s upcoming earnings report date?
AngioDynamics’s upcoming earnings report date is Oct 01, 2026 which is in 26 days.
How were AngioDynamics’s earnings last quarter?
AngioDynamics released its earnings results on Jul 14, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.02.
Is AngioDynamics overvalued?
According to Wall Street analysts AngioDynamics’s price is currently Undervalued.
Does AngioDynamics pay dividends?
AngioDynamics does not currently pay dividends.
What is AngioDynamics’s EPS estimate?
AngioDynamics’s EPS estimate is -0.11.
How many shares outstanding does AngioDynamics have?
AngioDynamics has 41,332,390 shares outstanding.
What happened to AngioDynamics’s price movement after its last earnings report?
AngioDynamics reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went up 1.761%.
Which hedge fund is a major shareholder of AngioDynamics?
Currently, no hedge funds are holding shares in ANGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AngioDynamics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (33.84% Upside)
$21.00 (33.84% Upside)
Blogger Sentiment
Bullish
ANGO Sentiment 67%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 816.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $344.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AngioDynamics
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
ANGO Company Deck
ANGO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong, above-market growth in Med Tech platforms (notably NanoKnife, Auryon, and AlphaVac), improving gross margins and a materially higher adjusted EBITDA for the year, plus a debt-free balance sheet and positive cash generation in Q4. Offsetting these positives are ongoing GAAP losses, tariff headwinds (~$4.8M), higher operating expenses, lumpiness in some product lines (AngioVac, capital equipment), and modest full-year cash generation. Management provided constructive FY2027 guidance with continued Med Tech growth and maintained investments in clinical R&D. Overall, the positive operational momentum, clinical progress, margin expansion, and improved adjusted EBITDA notably outweigh the headwinds and remaining losses.View all ANGO earnings summariesANGO Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$21.00
▲(33.84% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
InfuSystem Holdings
―
Orasure Technologies
―
Stereotaxis
―
Utah Medical Products
―
Sanara MedTech
―
Ownership Overview
5.73% Insiders
15.89% Mutual Funds
38.87% Other Institutional Investors
27.15% Public Companies and
Individual Investors











